Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges

Author:

Halabi Susan12ORCID,Zhou Jinyi1,He Yijie1,Bressler Linda R3,Hernandez Adrian F2ORCID,Turner Nicholas A4,Hong Hwanhee12ORCID

Affiliation:

1. Department of Biostatistics and Bioinformatics, Duke Health, Durham, NC, USA

2. Duke Clinical Research Institute, Duke Health, Durham, NC, USA

3. University of Illinois, Chicago, IL, USA

4. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

Abstract

Background/Aim The number of coronavirus disease 2019 deaths and cases continues to increase globally. Novel therapies are urgently needed to treat patients with coronavirus disease 2019. We sought to provide a critical review of trials designed during the coronavirus disease 2019 pandemic. Our primary goal was to provide a critical review of the landscape of clinical trials designed to address the coronavirus disease 2019 pandemic. Specifically, we were interested in assessing the design of phase II/III and phase III interventional trials. Methods We utilized the ClinicalTrials.gov database to include trials registered between 1 December 2019 and 11 April 2021 to survey the current landscape of clinical trials for coronavirus disease 2019. Variables extracted included: National Clinical Trial number, title, location, sponsor, study type, start date, completion date, gender group, age group, primary outcome, secondary outcome, overall status, and associated references. Results About 57% of studies were interventional, 14.5% were phase III trials, and the majority of the therapeutic trials included hospitalized patients. There were 52 primary composite outcomes and 285 unique interventions spanning 10 drug classes. The outcomes, disease severity, and comparators varied substantially across trials, and the trials were often too small to be definitive. Conclusion These findings are relevant as we strongly advocate for global coordination of efforts through the use of common platforms that enable harmonizing of endpoints, collection of common key variables and clear definition of disease severity to have clinically meaningful results from clinical trials.

Funder

Duke University

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Reference49 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

2. Risk for In-Hospital Complications Associated with COVID-19 and Influenza — Veterans Health Administration, United States, October 1, 2018–May 31, 2020

3. World Health Organization. Weekly operational update on COVID-19—22 February 2021, 2021, https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-22-february-2021

4. ClinicalTrials.gov, https://clinicaltrials.gov/

5. Remdesivir for the Treatment of Covid-19 — Final Report

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3